Carolyn Burns, MD
Cardiovascular Disease · Richmond, VANPI 1063453801
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,685 of the $40,958 with a category attached, or 87.1%. Amgen accounts for 93.8% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $20,222 and has fallen 94.9% since, to $1,032 in 2023. Among cardiovascular disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $220.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$38K
- Johnson & Johnson$389
- Regeneron Healthcare Solutions, Inc.$364
- Amarin Pharma, Inc.$308
- Pfizer$212
- AstraZeneca$205
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$35,68587%
- Travel & lodging$1,0303%
- Food & beverage$4,17010%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 64 | $38,399 |
| Johnson & Johnson | 19 | $389 |
| Regeneron Healthcare Solutions, Inc. | 12 | $364 |
| Amarin Pharma, Inc. | 13 | $308 |
| Pfizer | 11 | $212 |
| AstraZeneca | 11 | $205 |
| Novartis | 7 | $140 |
| Abbott | 5 | $98 |
| Lundbeck LLC | 5 | $98 |
| Regeneron | 1 | $95 |
| Esperion Therapeutics, Inc. | 5 | $89 |
| Boehringer Ingelheim | 4 | $79 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $73 |
| E.r. Squibb & Sons, L.L.C. | 4 | $72 |
| Sanofi-aventis U.S. LLC | 3 | $64 |
| Merck | 3 | $51 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Irhythm Technologies, Inc. | 2 | $39 |
| Atricure, Inc. | 2 | $39 |
| Gilead | 2 | $25 |
| Bayer | 1 | $19 |
| Livanova USA, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Itamar Medical Inc | 1 | $13 |
| Aegerion Pharmaceuticals, Inc. | 1 | $11 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,958 in reported general payments places this provider in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 163 | $98,871 |
| Praluent PenAlirocumab | 23 | $10,378 |
| Ezetimibe | 46 | $1,043 |
| Rosuvastatin Calcium | 54 | $477 |
| Atorvastatin Calcium | 13 | $126 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Richmond
- George VetrovecRichmond$2.3M
- Abdullah KhanRichmond$48K
- Robert LevittRichmond$23K
- Jason CookRichmond$18K
- Aaron SchatzRichmond$13K
- Hamid TaheriManassas$501K
- Cyrus HadadiNorfolk$360K
- Michael AyersCharlottesville$305K
- David LimCharlottesville$264K
- Alexander TruesdellFalls Church$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.